ImmunoCellular Therapeutics (NYSE: IMUC) reported Q2 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.